First Bladder Cancer Targeted Small Molecule Receives Full FDA Approval
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
First Bladder Cancer Targeted Small Molecule Receives Full FDA Approval
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
First Bladder Cancer Targeted Small Molecule Receives Full FDA Approval
In a recent announcement, Johnson & Johnson revealed that its small molecule inhibitor, Balversa (erdafitinib), has received comprehensive approval from the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with genetic variations in the FGFR3 gene, and whose disease has progressed following at least one line of systemic therapy.
Balversa is the first orally administered fibroblast growth factor receptor (FGFR) kinase inhibitor to receive approval and marks the inaugural targeted therapy for mUC patients with FGFR mutations.
This approval is based on the positive outcomes of the Phase 3 clinical trial (THOR). The study was a randomized, open-label, multicenter research initiative that included mUC patients with specific FGFR genetic variations, experiencing disease progression during or after first- or second-line treatment.
Results from the THOR trial indicate a significant improvement in overall survival and a 36% reduction in the risk of death when comparing Balversa to chemotherapy in patients who had previously received PD-1 or PD-L1 inhibitors during second-line treatment. Patients treated with Balversa had a median survival period 4 months longer than those receiving chemotherapy.
Common adverse reactions related to Balversa include elevated phosphate levels, nail disorders, oral mucositis, and diarrhea.
Balversa is a once-daily oral FGFR kinase inhibitor. Approximately 20% of mUC patients carry FGFR gene mutations, and Balversa achieves therapeutic effects by inhibiting FGFR. The therapy received Breakthrough Therapy Designation (BTD) from the FDA in 2018 and accelerated approval in April 2019.
First Bladder Cancer Targeted Small Molecule Receives Full FDA Approval
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.